Orlucent Demonstrates Accurate, Non-Invasive Detection in vivo of Melanoma-Related Activity Using First-in-Kind Handheld Mole Imaging System

LOS GATOS, Calif., Jan. 16, 2024 -- (Healthcare Sales & Marketing Network) -- In a first-in-human study, researchers at Orlucent, Inc. have demonstrated the viability of a novel handheld point-of-care molecular Skin Fluorescence Imaging (mSFI) System to n... Devices, Dermatology Orlucent , mSFI , molecular Skin Fluorescence Imaging, melanoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news